Literature DB >> 18931460

Promoter hypermethylation is not the major mechanism for inactivation of the FBXW7 beta-form in human gliomas.

Zhaodi Gu1, Kenichi Inomata, Hidetoshi Mitsui, Akira Horii.   

Abstract

FBXW7 has been reported to be a candidate tumor suppressor gene on 4q31. Three isoforms (alpha-form, beta-form, and gamma-form) of FBXW7 are produced from mRNAs with distinct 5' exons. Our previous study identified the specific suppression of the mRNA expression of the FBXW7 beta-form in human gliomas. Because this form is the major FBXW7 isoform in the human brain, we elucidated the silencing mechanisms for the FBXW7 beta-form in gliomas. No genetic alterations were found in the whole FBXW7 gene including putative promoter region of the beta-form. Treatments with 5-azacytidine and trichostatin A did not induce re-expression. A sodium bisulfite-modification assay indicated that CpG sequences in the promoter of FBXW7 beta-form were not methylated in glioma cells. Meanwhile we searched for the expression of FBXW7 and the sodium bisulfite sequences in normal human peripheral blood cells, and we surprisingly found that the mRNA expression of the FBXW7 beta-form was highly suppressed and the CpG sequences in the promoter region of the FBXW7 beta-form were heavily methylated. Our data suggest that the inactivation of the FBXW7 beta-form plays an important role in the pathogenesis of gliomas and that an unknown mechanism(s) other than mutation and methylation is the major cause of the suppression of the FBXW7 beta-form in gliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931460     DOI: 10.1266/ggs.83.347

Source DB:  PubMed          Journal:  Genes Genet Syst        ISSN: 1341-7568            Impact factor:   1.517


  5 in total

1.  Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Authors:  Irene Vázquez-Domínguez; Laura González-Sánchez; Pilar López-Nieva; Pablo Fernández-Navarro; María Villa-Morales; María Á Cobos-Fernández; Isabel Sastre; Mario F Fraga; Agustín F Fernández; Marcos Malumbres; María Salazar-Roa; Osvaldo Graña-Castro; Javier Santos; Pilar Llamas; José L López-Lorenzo; José Fernández-Piqueras
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

Review 2.  Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities.

Authors:  Ryan J Davis; Markus Welcker; Bruce E Clurman
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

3.  Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.

Authors:  Jingxiao Wang; Haichuan Wang; Michele Peters; Ning Ding; Silvia Ribback; Kirsten Utpatel; Antonio Cigliano; Frank Dombrowski; Meng Xu; Xinyan Chen; Xinhua Song; Li Che; Matthias Evert; Antonio Cossu; John Gordan; Yong Zeng; Xin Chen; Diego F Calvisi
Journal:  J Hepatol       Date:  2019-06-11       Impact factor: 25.083

Review 4.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 5.  Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.

Authors:  Jun Cao; Ming-Hua Ge; Zhi-Qiang Ling
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.